Become a Member

written by reader Stellar Biotechnologies – The real deal or just more tulip bulbs?

By theblindsquirrel, August 21, 2013

DISCLAIMER: I am long shares of SBOTF and may add to the position at any time.
”Even blind squirrels find an acorn every now and then”
OK, I know .. there is already plenty of discussion re Stellar Biotechnologies (SBOTF) on the site. Since Travis posted the tease from Nick Hodge in early July, the stock is up a hair over 100% (my Special Situation account sends many thanks for that one!). The reason I’m opening this thread is because the majority of comments from those of us interested or already invested in SBOTF are being posted under another wonderful – yet mostly unrelated – thread by Doc Gumshoe that talks about Alzheimers and possible causes/treatments/cures. Great stuff, but not fully germane to the topic of SBOTF. So, tho seperate the two discussions, I thought I’d try this so we can focus on each of the topics independantly.
That said, here’s some commentary about SBOTF that I have gleaned from the original tease, tracking the price action since July, reading member comments on this site, and studying anything and everything I can find about the Company and it’s product, Giant Keyhole Limpet Hemogobulin, a/k/a KLH.
First, a little peeve I’ve developed; the actual name of this animal that is the central focus of the business. I’ve noticed a trend of sorts by readers to refer to the Limpet as a ”snail”, ”escargot”, or something along those lines. While some may be using this as a light-hearted way of referring to the animal, it is not any of those. Please, use the proper name – as silly as it might sound. New readers could easily dismiss the entire idea and be misled otherwise. No disrespect meant to any who have done this, but I think it’s important we stay on track.
Now, some factoids for you.
If you haven’t done your due dilligence yet, the place to start is right here on this page. In the upper right you’ll see a box that says ”Teaser Tracking.” Click on that. The page that comes up is a list of the teases which Travis has posted over the past many months. Second from the top is the one re SBOTF. Some good tidbits of info right there. But what you want to do is look all the way over to the right and click on the link to the original tease posting. Open that and you’ll get the full story that Travis wrote when he first uncovered this tease (produced by Nick Hodge) and is a solid foundation of info about the company. Read it – two or three times to get an understanding of what SBOTF is all about.
Next, if you can find it, try and get a post that has the original video that Hodge did to tease the company with. In it, he (Hodge) interviews a couple of the company’s top executives and takes the cameras outside the room totalk with another employee about the ”farming” process that SBOTF has spent years and millions developing and patenting. You’ll get a pretty good visual inspection of the plant itself, the ”grow tanks”, and the Limpet. Good stuff. By the end you’ll have a fair overview of the company and what it does. FYI, the video tease runs about 40 minutes. It’s the first 25 minutes or so that will interest you. The remainder is what all teases consist of, overblown and repetitive pleas to get you to subscribe to the newsletter service that the promoter has to offer. Save yourself time and money by skipping that stuff.
A few takeaways from the video and additional research:
SBOTF has been around since the late 1990’s, working on how to extract the blood from the Limpet without killing them (they have done that and gotten patents on the process) and how to raise them in captivity in order to ensure a continuious supply of the animals to work with. This ”farming” process has, for the most part, been perfected and SBOTF can now raise them from fertilization of sperm and egg to maturity. They have a lifespan of some 30 years, and coupled with the patent-protected process they developed for extracting the blood without killing the Limpet, the company can now say with assurance that they can provide the Big Pharma with all the KLH they need to conduct clinical trials and produce the drugs they develop once FDA approval is granted. And – this is a big ”and” – they are the ONLY company in existence that can do this at the present time. The many patents they hold may ensure that to be the case for years to come.
Did I mention that KLH cannot be synthesized? So far nobody has been able to do that, so the supply of KLH from SBOTF seems to remain the only game in town.
Stellar Bio has yet to turn a profit. Sales and not much to write home about. That is mainly due to the small supply available and that SBOTF has focused on R&D in the past moreso than actual KLH production. That’s my best guess – I can’t verify that but seems to be the case. It is changing, however. The R&D is still in full swing, but the ability to produce and sell KLH is starting to ramp up as witnessed by increasing sales volume. It’ll take time but those increasing sales are coming.
In the wild (ocean floor), the Giant Keyhole Limpet has never been found ANYWHERE in the world other than in the small colony (estimated to be about 100,000 animals) which is just offshore from the Stellar Bio plant in Ventura County, CA. The enviromental community has been getting more and more concerned about the harvesting of the Limpets from this colony since there apparently aren’t any more around. Whisper talk about possible extinction have begun to surface, although no official governmental action regarding a ”protected specise” has yet been issued. This is why the farming of the animals has been crucial and why Stellar has such a leg up on any possible competition. If the Tree Huggers get hold of that idea, the ability to harvest the colony could – and probably would – be severely impacted.
Recent price and volume action has been fast and furious. As more and more people are becoming aware of the company by means of Hodges’ tease and thing such as this discussion, volume has had days that were near three times the average six months ago (175K shares average vs. some days now running around 500K). And most of this is upside volume indicating increasing demand for shares of a small float. This of course leads to highr prices as we are witnessing as I write.
For now, the gravy train is tearing down the track. The question is, when will demand for shares be curtailed as investor thirst for a bite of Limpet pie become satisfied? When will Nick Hodge back off this promotion, letting the press subside and therefore lessening investor awareness (the stock is not covered by any analyst, anywhere, that I can find, nor is it held by any mutual fund or investment management company). If and when this interest backs off, what effect will that have on the stock price? Trees don’t grow to the sky … or do they?
I can’t answer those questions. Just like you, I can only hold ’um and not fold ’um – yet. That day may come, and that is why I suggest anyone long the stock keep a DAILY eye on it. I’m making no prediction whatsoever about where the price will go over the next several weeks or months. In the interest of full disclosure, I have already taken some money off the table just to partially protect the quick profits I made since purchase. I sold about 30% of my initial position when that part became valued around 50% of my original investment. What remains is valued today right at the same $ amount I first put in. The amouunt I pulled out gives me full protection of some 50% of my original investment. Would I be better off today if I hadn’t done that? Yes. I would, because the price continues to rise. Will I be better of for having made thaat sale if the price stumbles and falls in the near future? Again, yes, I will – if the price falls. Some wise man once said ”you can’t go broke if you take profits” and I believe in that. Me, I don’t care for the idea of going broke, so I’m perfectly happy with this concept. No regrets about putting actual money in the bank, so to speak.
Comments? Concerns? Insights? Let the fun began!
Sincerely,
Your Resident Blind Squirrel
Jim Skelton

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

239 Comments
Inline Feedbacks
View all comments
Jana Brandao
Member
October 14, 2013 12:31 pm

Hey guys, is anyone out there? Eleven days since a post? This is the hard part, right? Sticking with it through ups, downs, and sideways? Anyone have any news or insight that the group could benefit from? I think that the addition of Stellar to the S&P/TSV Venture Index is a positive thing, no? Would love to hear from anyone!
JB

rfrose
October 14, 2013 2:00 pm

Hi Jana, yes this is the hard part. The waiting game – waiting for the right wave to come in so we can surf our way to prosperity (or at the least some cash advancement).
Hang in there, it may not have much movement until mid next year, and thus, why stocks are always a ‘long’ proposition. Unless, of course, you like to day trade or as I sometimes do, week trade, but this action is for those who sit and stare at graphs and stock tickers all day long. (which is for sure not me)

Add a Topic
5971
👍 192
Will
Member
Will
October 14, 2013 4:05 pm

Hi All,

Glad I found a support group. 🙂 I have bought in in a big way, first at 1.79 (the drop to 1.30 was gut wrenching) and added to cost down to about 1.71. However, everything I have perused through on the web and their website makes me believe this company is a real gem. I seem to recall that they are presenting at a conference in about a week, but I can’t seem to find that information now. Can anyone confirm that? If they make a breakthrough on a c. diff. vaccine, huge potential there alone. This is the only place I have seen a substantive discussion on Stellar.

Sean R.
Guest
Sean R.
October 15, 2013 1:55 pm

My comments from August 27th still apply…the roller coaster ride will continue. There is support at these levels and we won’t see much action unless there is very good news or the market makers decide to give it another run prior to a news release. We’re here long term so I’m not too concerned about the day to day.

Jana Brandao
Member
October 15, 2013 2:59 pm

Hi ya’ll. Just checking in, no changes, no panic. This is the 6th time I have tried to post. At some point I have inadvertently hit or touched something on the keyboard of my Dell XPS that completely wipes out my post and I have to start over. I wish to God someone could tell me what I’m doing wrong. Luckily for you, my precious allegory comparing investing in Stellar to baking a loaf of bead is MIA, and I’ll just say bye for now. JB

Add a Topic
5688
👍 192
Will
Member
Will
October 17, 2013 12:42 pm

Well Jim, you may have found another one. It has had a great run, but probably plenty to go. Nice couple of days on Stellar… Got a question for you or anyone else who may have done this. I ran some back of the envelope numbers and came up with anywhere from $22 to about $50 per share in 3-5 years. Here is how I came up with it (feel free to critique/add to this…) Using Stellar’s estimated yearly revenue (where there was a range I took the low end.) They estimate about 620mm per year / 70 mm shares = $8.85 per share gross revenue. Assuming we don’t get massively diluted. I have a problem determining expenses, but some large pharmas have about 25% net profit per share. I would assume at least that, and maybe more since Stellar is a small company (fewer employees, sales staff, etc.) IF (correct me here) their expenses are 50% gross revenue, then $4.42 net revenue per share X 10pe (avg. biotech pe) = $44 per share. At 25% it should be about $22 per share. Where did I go wrong there? (I am clearly not an analyst, and my first attempt to prognosticate.) Thanks for any feedback anyone can offer.

Aldo
Guest
Aldo
October 17, 2013 7:04 pm

Jim, I believe its Brian Nichols and not Brian Williams who authored the “Pimavanserin” story.

Just in case some people had issue finding it.

Thanks for your interesting points of view everyone. I enjoy this site very much.

AH
Guest
AH
October 18, 2013 1:52 pm

Hello Jim,
Thank you for the ACAD note. I have been trying to look up the latest FDA reports or news on this but have not found anything. They have eschewed final Phase 3 trials and have gone directly to FDA approval. So please could you let me know if you have anything on
a.) What is the current status of the drug with respect to FDA approval? What is the likelihood of approval by FDA?
b.) When will the approval (if provided) by FDA come through?
c.) In the trials: the delusion score dropped by 5.79 points using Pima while scores for placebo patients only dropped 2.73 points. Could anybody throw light on this? and if this drug is extremely beneficial to patients that it would force doctors everywhere to recommend this or is it just another pill (addition to Risperdal, Zyprexa, Abilify) with little side effect?
d.) Not so sure about the pricing stats though. It is mentioned that it will command premium pricing ($1000 per month!). Per year = $12000 for just one pill! That is a lot of money for just one pill. Not sure if the patients (i sure as cant!) can afford for just one pill considering they have a whole of pills and other expenses (i feel for them).
I also came across a comment (by JJ PositionTrade) which seems to support this fact and make sense
“Zyprexa, Abilify, Risperdal, etc. are highly potent drugs to treat schizophrenia, a far more debilitating disease than Parkinson’s or Alzheimer’s psychosis. I’m not belittling those who have it, but you need much more power than what pimavanserin offers to treat schizophrenia alone. They will not get $1000/mo for this drug to treat Parkinson’s psychosis. It is treated now with low doses of Seroquel for very little per month, so why would any insurer add $12000/yr to the bill of a Parkinson’s pt who is already paying $20K to $30K per year for their current PD meds and other diseases? Making comparisons to Parkinson’s psychosis and schizophrenia in your pricing models is a huge mistake. These are two completely different diseases”
Another comment ” Pimvanserin has shown that it works pretty well in Parkinson’s related psychosis. To extrapolate this result to other forms of psychosis is a big jump. Psychosis is a syndrome; and like all syndromes they tend to have some similar features but mechanisms may be quite different.”
My Take: From the above comments + LET me remind you that markets outside US are extremely different and very few can afford this costly pill (For $12k one can get a full time nurse to take care of AZ, PK patient for a whole year). So if this is true, the evaluation drops by atleast 50%
Sorry, if i am copy pasting other users’ comments but these seem to be significant comments. Also, my knowledge is limited to reading reports and comments. I am not involved in the pharmaceutical industry.
So considering all this, doesn’t the current stock price reflect all the uptake + there is the additional huge risk of FDA approval.??

Will: Thank you for your numbers but $600 million sales is a bit too high. I had estimated $300 million and also you are missing out on debt and R&D expenses (which i think is significant say 25%). But from my analysis i had an estimate of $10 per share if they were able to generate enough sales of KLH and if (BIG IF) a blockbuster vaccine using KLH is developed (most of them are in Stage 1 and 2) :(. Long way off..
Thank you,
AH

Add a Topic
3022
Add a Topic
3022
Add a Topic
3022
David Brown
Guest
October 21, 2013 12:41 pm
Reply to  AH

Good news from the company regarding promising preclincal tests with lab mice to the C difficile vaccine. Stellar will be presenting this week at a big C. Diff. Conference so good timing with the initial results. The stock has been trending up nicely lately and this news should add support. I’m expecting $2 a share or more by year’s end (sustainable, not just a one day blip $2 plus). There are still miles to go even re. this first vaccine, but the ride is certainly enjoyable! The weekly gyrations of the market can be unsettling, but the upside potential of this company remains very solid. KLH shows tremendous promise in a broad range of treatments. The talking heads on CNBC, Bloomberg and various stock services wont touch this stock until it hits close to $10 so enjoy the profits as you have gotten in close to the ground floor even if you just get in today!

Add a Topic
5971
Add a Topic
1278
Add a Topic
6139
Will
Member
Will
October 21, 2013 12:47 pm
Reply to  AH

Thanks for the reply AH. I used the lower range of numbers that Stellar estimated (in their investor presentation) as yearly revenue. (Though, to your point, underestimating that by half is probably prudent.) Could you clarify your statement on expenses? I used 25% of gross revenue as net profit, meaning 75% expense ratio (Amgens latest quarterly announcement was about there.) This is where the $22/share figure comes from. Do you mean 25% of revenue is the debt and R&D expenses? Also Celldex is currently in phase 3 trials for Glioblastoma and OBI looks like they are enrolling for phase 3 for breast cancer. But you are right, most are in phase I/II… If your expense numbers are the same as mine (on the 75% of gross revenue) and I cut my estimate to 300mm then our numbers are essentially the same at about $10-$11/share.

Add a Topic
1279
Add a Topic
5809
Add a Topic
3359
David Brown
Guest
October 22, 2013 1:43 pm

Stellar Biotch remains stellar–above $1.90 and still rising, another pleasant surprise. I had expected $2 by year’s end but once again it’s beating my estimates. Jim and others who like small biotechs before the Street discovers them–I like CTIX over ACAD Jim. Cellceutix is only trading at $1.80 and has a very promising pipeline of four phase 1,2, 2/3 drugs plus many other compounds showing promise in pretrials. Their main focus is in hard to treat illnesses–espc. in oncology, dermatology and antibiotics. I haven’t bought yet but I’m strongly considering investing in CTIX.
Other speculatives I do own are in the green energy area–Natcore (NTCXF) is a very promising solar tech company that has technologies that can make solar compete with other forms of energy even without government subsidies. The stock has been soaring even more than Stellar in recent days, perhaps due to China no longer as heavily subsidizing their solar industry. NTCXF is currently selling right around $1 per share.
Clearsign Combustion (CLIR) has been around longer and sells for about $7.40 a share. It is also an “energy technology” company that has technology that can make any flame based energy dramatically more efficient and dramatically less polluting. If their claims are even close to being true, the coal industry and oil and gas refiners (among others) could really benefit from their technology. This stock hasn’t been a great performer in recent months but is up 40% for the year and it certainly has a big upside. I like all four of these microcaps as, in my mind, they have tremendous upsides with proven technologies or very promising drugs/compounds. While there are certainly big risks in any microcap–I don’t see as much risk in any of these companies as I do in many other microcaps since they all have very useful products and/or technologies that should make considerable money as they benefit society. That’s a nice combination. Stellar is by far my biggest holding but I lke the other three quite a bit as well.

Add a Topic
4517
Add a Topic
5971
Add a Topic
108
Texast
Texast
October 22, 2013 2:55 pm

Thanks for all the tips. A few months ago my mom was diagnosed with an aggressive cancer and I came across the keyhole limpets research. I then looked for analysts interested which led me here. I picked this stock up at $1.25 a while back and then added more at $1.55 after doing research and following the ups and downs. Sadly my mom passed after a valiant effort. I hope one day these limpets help others. I am a very rational/cautious investor and have never bought a penny stock until now. Their story is inspiring. I know my mom’s illness made me more emotional but felt why not. I usually hold long and don’t worry about my account. Strangely this little stock gets me up each day to see how it’s doing. One day at a time. Thanks Jim aka blind squirrel for your analysis and belief in this stock. I’m a fan of yours and stock gumshoe now here in Austin.

Add a Topic
3397
Add a Topic
285
Add a Topic
5971
David Brown
Guest
October 22, 2013 4:48 pm

Stellar’s knocking on the $2 door at the close today and the trend continues steadily up. A skeptic might point to the euphoria in 2010 when the stock opened and went from about .25 to $1.50 in late Dec. and then spent the next two years steadily backtracking to about .40. I would argue that the 2013 rally is much different as now there is a lot more scientific evidence, there are now at least 2 billionaire investors with strong positions, a Taiwanese Biotech Company linked in and a promising C Diff. vaccine in development. There will still be volatility, but hopefully a lot less than right around the Private Placement. Market timers will still try to benefit from the swings and manipulate the price when they can. My hunch is that this will lessen with the stock price now in the $2 range.
Happy investing giant keyhole limpet lovers.

Add a Topic
5971
Add a Topic
5971
sparky
October 22, 2013 8:13 pm

i got an email today that announced that it has been added to in an index. Funds that track the index would need to buy the shares.

👍 4
toberle
Member
toberle
November 5, 2013 4:49 pm
Reply to  sparky

What has happened to the dialogue on Stellar. Has it stopped or can it be found elsewhere on the website?
Thanks,
Tomo

👍 5
David Brown
Guest
November 5, 2013 6:21 pm

Stellar Biotech (SBOTF) remains a great long term investment Tom. It’s price seems to have paused in the 1.85-1.99 range of late as there hasn’t been significant price moving news after the announcement that the pretrails for the C Difficile Vaccine look very good. They just had a management announcement today but I don’t see that as making much difference in stock movement. It does look like the company continues to position itself for significant growth which is promising. Stellar appears to have excellent scientists and excellent management for a microcap along with very impressive vaccination possibilities for KLH in the future. These things make this tiny company one to watch for years to come.

Add a Topic
5971
Add a Topic
6113
David Brown
Guest
November 18, 2013 5:32 pm

Stellar Biotechnologies has held up well in a rough two month period for many biotech stocks. This bodes well for our favorite microcap biotech company : ) Once the sector warms up, I expect Stellar to easily reach $2 and any partnerships or other good news coming in will mean another significant rise in the stock price. Hang in there limpet land!

Add a Topic
5971
Add a Topic
282
AH
Guest
AH
November 20, 2013 11:24 am

Hey Jim,
Your notes make for quite a reading! SBOTF seems to be in a decline and has reached the 1.50 mark. But still hopeful for it in the long run. NASDAQ , DOW all seem to be going up except the stocks i own 🙂 Did you get into ACAD? I have been watching it for a while but have not made an entry into it.
Cheers,
AH

Add a Topic
4194
Add a Topic
4194
David Brown
Guest
November 20, 2013 12:08 pm

Apparently many SBOTF warrants have been exercised recently and this has diluted the market share. Also, many microcaps have been punished in the past several days. My favorite other two micros–Natcore and ClearSign have also had a very rough week. Hang in there folks, big swings are par for the course with the tiny companies. Buy low Sell high–not the other way around folks! If you have confidence in the long term prospects of a company, don’t panic.

Add a Topic
3229

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info  
5
0
Would love your thoughts, please comment.x
()
x